Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATHE
stocks logo

ATHE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.430
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 3.430
sliders
Low
12.00
Averages
12.00
High
12.00
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$8 → $12
2025-01-30
Reason
Maxim Group
Jason McCarthy
Price Target
$8 → $12
2025-01-30
Maintains
Strong Buy
Reason
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$8
2024-12-12
Reason
Maxim Group
Jason McCarthy
Price Target
$8
2024-12-12
Initiates
Strong Buy
Reason
Maxim initiated coverage of Alterity Therapeutics with a Buy rating and $8 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alterity Therapeutics Ltd (ATHE.O) is -4.13, compared to its 5-year average forward P/E of -18.96. For a more detailed relative valuation and DCF analysis to assess Alterity Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.96
Current PE
-4.13
Overvalued PE
82.47
Undervalued PE
-120.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.79
Current EV/EBITDA
-3.41
Overvalued EV/EBITDA
0.78
Undervalued EV/EBITDA
-2.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.76
Current PS
0.00
Overvalued PS
17.72
Undervalued PS
1.80
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ATHE News & Events

Events Timeline

(ET)
2025-11-10
07:56:15
Alterity Therapeutics Shares Findings on OH from ATH434-201 Trial
select
2025-10-31 (ET)
2025-10-31
07:29:07
Alterity Therapeutics announces cash reserves of A$54.46 million as of September 30.
select
2025-10-09 (ET)
2025-10-09
07:29:15
Alterity Therapeutics Reveals Findings from Phase 2 Trial of ATH434
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-31Newsfilter
Alterity Therapeutics: Q1 FY26 Cash Flow Report - Appendix 4C

  • Clinical Trial Results: New analysis from the ATH434-201 trial shows strengthened efficacy at a high dose for treating Multiple System Atrophy (MSA), with positive outcomes also reported in the ATH434-202 open-label trial for advanced MSA patients.

  • Market Potential: An independent assessment indicates a potential peak sales opportunity of USD $2.4 billion for ATH434 in the MSA market, driven by strong physician interest based on Phase 2 trial results.

  • Regulatory Engagement: Alterity Therapeutics is actively engaging with the U.S. FDA to discuss necessary data for advancing ATH434 into Phase 3 trials, following a series of Type C meetings to align on clinical development topics.

  • Financial Position: As of September 30, 2025, Alterity reported a cash balance of A$54.56 million, with operating cash outflows of A$5.34 million for the quarter, and successfully raised A$20 million from a strategic placement to support its programs.

[object Object]
Preview
9.0
10-09Newsfilter
Alterity Therapeutics Showcases Encouraging Results from ATH434 Phase 2 Trial at the 2025 International Congress on Parkinson's Disease and Movement Disorders

  • ATH434 Clinical Trial Results: Data from the Phase 2 trial of ATH434 in Multiple System Atrophy (MSA) show it slows disease progression and stabilizes orthostatic hypotension, with significant improvements observed in clinical endpoints compared to placebo.

  • Neuroimaging and Biomarker Analysis: Advanced neuroimaging and biomarker assessments in the trial enhance the understanding of MSA diagnosis and track disease evolution, indicating a multimodal approach may improve diagnostic accuracy.

[object Object]
Preview
9.0
10-02Newsfilter
Alterity Therapeutics to Present Several Talks at the 2025 International Congress on Parkinson's Disease and Movement Disorders

  • Clinical Trial Presentation: Data from Alterity Therapeutics' ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders, highlighting its potential as a first-ever treatment for MSA.

  • Efficacy and Safety Results: The trial demonstrated significant clinical efficacy, improved motor performance, and a favorable safety profile for ATH434, which is designed to inhibit protein aggregation associated with neurodegeneration.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alterity Therapeutics Ltd (ATHE) stock price today?

The current price of ATHE is 3.43 USD — it has decreased -1.55 % in the last trading day.

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s business?

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

arrow icon

What is the price predicton of ATHE Stock?

Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s revenue for the last quarter?

Alterity Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s earnings per share (EPS) for the last quarter?

Alterity Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Alterity Therapeutics Ltd (ATHE)'s fundamentals?

The market is revising No Change the revenue expectations for ATHE for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.66%.
arrow icon

How many employees does Alterity Therapeutics Ltd (ATHE). have?

Alterity Therapeutics Ltd (ATHE) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Alterity Therapeutics Ltd (ATHE) market cap?

Today ATHE has the market capitalization of 62.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free